Dose Cancer Research Results

Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
375- AgNPs,  ALA,    Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
mtDam↑, ROS↑, *toxicity↓, Dose∅, selectivity↑,
1556- Api,    Dissolution and antioxidant potential of apigenin self nanoemulsifying drug delivery system (SNEDDS) for oral delivery
- Analysis, NA, NA
*BioAv↑, *Dose∅,
1553- Api,    Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy
- Review, NA, NA
Dose∅, TumVol↓, Dose∅, COX2↓, Hif1a↓, TumCCA↑, P53↑, P21↑, Casp3↑, DNAdam↑, TumAuto↝,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1543- Api,    Therapeutical properties of apigenin: a review on the experimental evidence and basic mechanisms
- Review, NA, NA
TNF-α↓, IL1β↓, IL6↓, IL10↓, COX2↓, iNOS↓, Inflam↓, Dose∅, Dose∅,
1541- Api,  EGCG,    Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence
- Human, NA, NA
OS↑, Remission↓, Dose∅,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
1583- Citrate,    Extracellular citrate and metabolic adaptations of cancer cells
- Review, NA, NA
Warburg↓, OXPHOS↓, Dose∅, TumCP↓, ATP↓, eff↑, Apoptosis↑, TumCG↓, PFK1↓,
1574- Citrate,    Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway
- in-vitro, Lung, A549 - in-vitro, Melanoma, WM983B - in-vivo, NA, NA
TumCG↓, eff↑, T-Cell↑, p‑IGF-1R↓, p‑Akt↓, PTEN↑, p‑eIF2α↑, OCR↓, ROS↓, ECAR∅, IL1↑, TNF-α↑, IL10↑, IGF-1R↓, eIF2α↑, PTEN↑, TCA↓, Glycolysis↓, selectivity↑, *toxicity∅, Dose∅,
1569- Cu,    Copper Nanoparticles as Therapeutic Anticancer Agents
- Review, NA, NA
Dose∅, Dose∅, ROS↑,
1598- Cu,    Targeting copper in cancer therapy: 'Copper That Cancer'
- Review, NA, NA
eff↓, eff↑, Dose∅, eff↑, angioG↑, ROS↑,
1516- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
1776- MEL,    Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis
- Review, NA, NA
Remission↑, OS↑, neuroP↑, VEGF↓, KISS1↑, TumCP↓, ChemoSideEff↓, radioP↑, Dose∅, *ROS↓, DNArepair↑, ROS↑,
1805- NarG,    Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
- in-vitro, Ovarian, A2780S - in-vivo, NA, NA
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
1812- Oxy,    Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer
- in-vitro, Lung, A549 - in-vivo, Lung, NA - in-vitro, NA, BEAS-2B
TumCG↓, CD31↑, P53↓, Dose∅, other↑, Apoptosis↑, Hif1a↑, selectivity↑,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GSH↓, 1,   NRF2↓, 1,   OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 6,   SIRT3↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   MMP↓, 2,   mtDam↑, 1,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR∅, 1,   Glycolysis↓, 1,   PFK1↓, 1,   TCA↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 4,   Bak↑, 1,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 1,   BIM↑, 1,   Casp3↑, 3,   Casp8↑, 1,   Casp9↑, 1,   CK2↓, 1,   Cyt‑c↑, 3,   iNOS↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   survivin↓, 1,   Telomerase↓, 2,  

Transcription & Epigenetics ⓘ

H3↓, 1,   KISS1↑, 1,   other↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 1,   p‑eIF2α↑, 1,   HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

LC3B↑, 1,   p62↑, 1,   TumAuto↑, 1,   TumAuto↝, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   DNArepair↑, 1,   DNMTs↓, 1,   P53↓, 1,   P53↑, 2,   p‑P53↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 1,   SIRT6↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 2,   FOXO3↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   p‑IGF-1R↓, 1,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 2,   PTEN↑, 3,   p‑STAT3↓, 1,   TumCG↓, 3,   TumCG↑, 1,  

Migration ⓘ

CD31↑, 1,   FAK↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 2,   RIP3↑, 1,   p‑RIP3↑, 1,   TumCMig↓, 1,   TumCP↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   angioG↑, 1,   EGFR↓, 1,   Hif1a↓, 3,   Hif1a↑, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL1↑, 1,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   T-Cell↑, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv∅, 1,   Dose∅, 16,   eff↓, 3,   eff↑, 13,   Half-Life∅, 1,   selectivity↓, 1,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

ChemoSideEff↓, 1,   neuroP↑, 1,   OS↑, 2,   radioP↑, 1,   Remission↓, 1,   Remission↑, 1,   toxicity∅, 2,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 124

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 2,  

Core Metabolism/Glycolysis ⓘ

LDH↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   Dose∅, 2,  

Clinical Biomarkers ⓘ

LDH↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 7

Scientific Paper Hit Count for: Dose, Dosage
6 Apigenin (mainly Parsley)
2 EGCG (Epigallocatechin Gallate)
2 Citric Acid
2 Copper and Cu NanoParticles
1 Silver-NanoParticles
1 Alpha-Lipoic-Acid
1 Metformin
1 Melatonin
1 Naringin
1 Oxygen, Hyperbaric
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:1114  State#:%  Dir#:6
  wNotes=0  sortOrder:rid,rpid

 

Home Page